ATE179892T1 - Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis - Google Patents

Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis

Info

Publication number
ATE179892T1
ATE179892T1 AT93112169T AT93112169T ATE179892T1 AT E179892 T1 ATE179892 T1 AT E179892T1 AT 93112169 T AT93112169 T AT 93112169T AT 93112169 T AT93112169 T AT 93112169T AT E179892 T1 ATE179892 T1 AT E179892T1
Authority
AT
Austria
Prior art keywords
lipid
glycoaminoglycans
bonded
treatment
rheumatoid arthritis
Prior art date
Application number
AT93112169T
Other languages
English (en)
Inventor
Shigehisa Aoki
Shinichi Iwasaki
Nobuo Sugiura
Sakaru Suzuki
Koji Kimata
Original Assignee
Seikagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Kogyo Co Ltd filed Critical Seikagaku Kogyo Co Ltd
Application granted granted Critical
Publication of ATE179892T1 publication Critical patent/ATE179892T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93112169T 1992-07-30 1993-07-29 Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis ATE179892T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20355892A JP3714683B2 (ja) 1992-07-30 1992-07-30 抗リウマチ剤

Publications (1)

Publication Number Publication Date
ATE179892T1 true ATE179892T1 (de) 1999-05-15

Family

ID=16476131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93112169T ATE179892T1 (de) 1992-07-30 1993-07-29 Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis

Country Status (7)

Country Link
US (1) US5470578A (de)
EP (1) EP0581282B1 (de)
JP (1) JP3714683B2 (de)
KR (1) KR940005281A (de)
AT (1) ATE179892T1 (de)
CA (1) CA2101482A1 (de)
DE (1) DE69324859T2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011096A1 (en) * 1995-09-19 1997-03-27 Seikagaku Corporation Anti-inflammatory agent
US5869273A (en) * 1996-09-13 1999-02-09 Glyko, Inc. Chondroitin sulfate as a marker of bone resorption
EP1006183A1 (de) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante, lösliche Fc-Rezeptoren
JP3032824B1 (ja) * 1999-01-28 2000-04-17 東京医科歯科大学長 骨誘導促進剤
RU2197238C2 (ru) * 1999-11-22 2003-01-27 Российский научный центр "Восстановительная травматология и ортопедия" им. академика Г.А. Илизарова Способ профилактики и лечения остеоартроза, средство для его осуществления и способ получения средства для лечения остеоартроза
US7393938B2 (en) 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7608598B2 (en) * 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US9040078B2 (en) 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
EP2845596A3 (de) * 2000-01-10 2015-07-15 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Verwendung von Lipidkonjugaten bei der Behandlung von Krankheiten
US8304395B2 (en) * 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US20060189568A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US8501701B2 (en) * 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US7811999B2 (en) 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8916539B2 (en) 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
RU2209433C2 (ru) * 2000-06-19 2003-07-27 Российский научный центр "Восстановительная травматология и ортопедия" им. акад. Г.А.Илизарова Способ определения показаний к внутрисуставному введению хондропротекторов на основе гидролизата гликозаминогликанов хряща
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US8883761B2 (en) * 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
US20040105883A1 (en) * 2001-04-17 2004-06-03 Ping Gao Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
US6607745B2 (en) 2001-05-18 2003-08-19 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
KR20030046810A (ko) * 2001-12-06 2003-06-18 은삼제약 주식회사 콘드로이친 황산의 분해산물을 포함하는 관절염 예방 또는치료용 약학적 조성물
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
RU2205609C1 (ru) * 2002-04-30 2003-06-10 Юрьев Валерий Андреевич Способ лечения суставных осложнений ревматических заболеваний
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
JP4511470B2 (ja) * 2003-10-29 2010-07-28 帝人株式会社 ヒアルロン酸化合物、そのハイドロゲルおよび関節軟骨損傷治療用材料
WO2005066214A1 (ja) * 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
CA2558497A1 (en) * 2004-03-05 2005-09-15 Synthes (U.S.A.) Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
CA2587883A1 (en) * 2004-11-17 2006-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusale M Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma
JP4902134B2 (ja) * 2005-04-25 2012-03-21 帝人株式会社 癒着防止材
EA200800489A1 (ru) * 2005-08-03 2008-12-30 Морриа Байофармасьютикалс Применение липидных конъюгатов при муковисцидозе и их приложения
CN1771986A (zh) * 2005-10-28 2006-05-17 凌沛学 口服关节功能保护剂
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
AU2007320737B2 (en) * 2006-11-14 2014-04-03 Celsus Therapeutics Plc Contact lens compositions
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
RU2350271C1 (ru) * 2007-08-20 2009-03-27 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова Федерального агентства по высокотехнологичной медицинской помощи", ФГУ "РНЦ "ВТО" им. акад. Г.А. Илизарова Росмедтехнологий" Способ лечения ранних стадий остеоартроза тазобедренного сустава
JP2012526819A (ja) 2009-05-11 2012-11-01 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド 脂質−ポリマー複合体、その調製、及びその使用
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282482B1 (de) * 1985-10-24 1992-01-22 Medical Research Council Biochemisches reagenzmittel
GB2201919A (en) 1987-02-07 1988-09-14 David Barke Computer stationery
JP2953702B2 (ja) * 1989-01-20 1999-09-27 生化学工業株式会社 合成コンドロイチン硫酸プロテオグリカンを含有する組織癒着防止剤
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same

Also Published As

Publication number Publication date
JP3714683B2 (ja) 2005-11-09
AU668963B2 (en) 1996-05-23
CA2101482A1 (en) 1994-01-31
AU4431493A (en) 1994-02-03
US5470578A (en) 1995-11-28
DE69324859D1 (de) 1999-06-17
DE69324859T2 (de) 1999-10-07
EP0581282B1 (de) 1999-05-12
KR940005281A (ko) 1994-03-21
JPH0672893A (ja) 1994-03-15
EP0581282A1 (de) 1994-02-02

Similar Documents

Publication Publication Date Title
DE69324859D1 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
HU9203074D0 (en) 2-substituted indene-2-mercapto-acetamide being inhibitors of encefalinase and ace
ATE174330T1 (de) Herbizide, substituierte aryl-haloalkylpyrazole
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69224080D1 (de) Verwendung von nsaid zur behandlung von demenz
DE69214397D1 (de) 2-Substituierte Indane-2-Carboxyalkyl-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
NO912758D0 (no) Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
IT8122675A0 (it) Mercaptoacil derivati di varie proline 4 sostituite e relative composizioni utili per il trattamento dell'ipertensione.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
FI891813L (fi) Mikro-organismeja tappava/mikro-organismien kasvua estävä koostumus teollista käyttöä varten sekä menetelmä mikro-organismien tappamiseksi tai niiden kasvun estämiseksi
ATE157876T1 (de) Wirkstofffreie liposomen zur behandlung von atherosklerose
DE69500511D1 (de) Phosphatdiester zur Behandlung von proliferativen Erkrankungen der Epidermis
MX9301298A (es) Seudopeptidos, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
EP0577699A4 (de) Zusammensetzungen und verfahren zur hemmung der aktivierung des aktiven faktors xiii.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties